Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628751 | 0.86 | TRPM8 (0.56) | TRPM8EPHX1TRPV1MAPK1 | |
| SCHEMBL2628759 | 0.84 | TRPM8 (0.54) | TRPM8EPHX1TRPV1MAPK1 | |
| SCHEMBL15133478 | 0.84 | TRPM8 (0.54) | TRPM8EPHX1TRPV1MAPK1P2RX4 | |
| SCHEMBL2628644 | 0.84 | TRPM8 (0.54) | TRPM8EPHX1TRPV1MAPK1P2RX4 | |
| SCHEMBL2628635 | 0.82 | TRPM8 (0.52) | TRPM8EPHX1TRPV1MAPK1P2RX4 | |
| SCHEMBL2628771 | 0.82 | TRPM8 (0.57) | TRPM8EPHX1TRPV1P2RX4 | |
| SCHEMBL2628680 | 0.78 | KMT2A (0.56) | TRPM8EPHX1TRPV1MAPK1 | |
| SCHEMBL15133482 | 0.78 | KMT2A (0.56) | TRPM8EPHX1TRPV1MAPK1 | |
| SCHEMBL14664188 | 0.76 | TRPM8 (0.57) | TRPM8EPHX1 | |
| SCHEMBL2628678 | 0.76 | TRPM8 (0.57) | TRPM8EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 8/4885EPHX1 2270/4885TRPV1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.